Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Several possible studies

Story checked

Algorithmic tool may improve screening of patients for an Alzheimer's clinical trial (opens in a new tab)

medicalxpress.com · 2026-09-09

Short answerEvidenceSource

Short answer

Several possible studies

No clear answer.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Several studies could be the source of this story.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Open claim evidence
3

Search result

Several studies could fit.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Related research

Research nearby

The papers it could be

Nearby papers when the source is unclear.

and 15 more considered

Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 4Not checkedA new blood-based screening algorithm dramatically reduced the number of unnecessary PET scans needed to recruit patients at risk of Alzheimer's disease for a clinical trial, according to research from scientists at the Keck School of Medicine of USC published in Alzheimer's & Dementia.View evidenceHide evidence

As stateddramatically reduced

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 4Not checkedWhen the algorithm was used to recruit participants, it cut the rate of people who received a PET scan but did not qualify for the trial from more than 70% to 31%.View evidenceHide evidence

As statedfrom more than 70% to 31%

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 4Not checkedThe AHEAD 3-45 clinical trial is a phase 3 international study testing whether earlier treatment with lecanemab could lead to better outcomes in people with amyloid-beta buildup before symptoms appear.View evidenceHide evidence

As statedphase 3 international study

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 4Not checkedThe screening tool incorporated amyloid-beta ratio, p-tau217, age, and APOE4 carrier status, and was developed using data from 1,080 AHEAD participants and validated in an independent dataset from the Wisconsin Registry for Alzheimer's Prevention study.View evidenceHide evidence

As stated1,080 AHEAD participants

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.

Nearby research

No exact source, but these papers are close.

PubMed, Crossref, Europe PMC · 15 candidate papers

And 10 more candidates considered.